Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
Condition:   Myelogenous Leukemia, ChronicIntervention:   Drug: Peginterferon alfa-2aSponsor:   Hoffmann-La RocheCompleted - verified April 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2016 Category: Research Source Type: clinical trials